

Filed: June 28, 2024

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

FORESIGHT DIAGNOSTICS INC.,

Petitioner,

v.

PERSONALIS, INC.

Patent Owner.

Case IPR2023-00546
U.S. Patent No. 10,450,611

PATENT OWNER'S UPDATED EXHIBIT LIST

EXHIBIT LIST

Exhibit No.	Description
2001	The Scientist Staff, “2022 Top 10 Innovations,” Dec. 12, 2022, available at https://www.the-scientist.com/features/2022-top-10-innovations-70792
2002	Swanton, C., “Plasma-Derived Tumor DNA Analysis at Whole-Genome Resolution,” <i>Clinical Chemistry</i> 59:1 6-8 (2013)
2003	K.C. Allen Chan et al., “Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing,” <i>Clinical Chemistry</i> (2013)
2004	Exemplary Embodying Product Claim Chart for U.S. Patent No. 10,450,611
2005	Tim Forshew, et al., “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA,” <i>Science Translational Medicine</i> (2012), EX1030, from related <i>Foresight Diagnostics Inc. v. Personalis, Inc.</i> , IPR2023-00545
2006	Matthew W. Anderson & Iris Schrijver, “Next Generation DNA Sequencing and the Future of Genomic Medicine,” <i>Genes</i> (2010)
2007	Dennis Lo, “Cancer Genome Scanning in Plasma, <i>Clinical Chemistry Journal</i> ,” Jan. 3, 2013 https://www.aacc.org/science-and-research/clinicalchemistry/clinical-chemistry-podcasts/2013/cancer-genomescanningin-plasma-detection-of-tumor-associated-copynumberaberrations
2008-2009	RESERVED

Exhibit No.	Description
2010	<i>Curriculum Vitae</i> of Dr. Henry Morrice Furneaux
2011-2034	RESERVED
2035	Declaration of Dan Norton
2036-2150	RESERVED
2151	Foresight Diagnostics, About, https://foresight-dx.com/about
2152	RESERVED
2153	“Personalis MRD Assays to Support UK’s TRACERx ctDNA Monitoring Study,” Precision Medicine Online, April 5, 2023
2154	“Personalis, AstraZeneca Extend Collaboration Around Residual Cancer Detection Test,” GenomeWeb, March 7, 2023
2155	RESERVED
2156	Labrousse, “MATRIX plasma-in-plasma contrived samples assessment and detection of MRD using the Personalis NeXT Personal assay,” American Society of Clinical Oncology, e15056, 2023.
2157-2162	RESERVED

Exhibit No.	Description
2163	Transcript of the deposition of John Quackenbush, Ph.D., taken on October 20, 2023.
2164	Bratman and Alizadeh and Diehn, Expert Rev Mol Diagn 15:715-719 (2015)
2165	Chaudhuri and Alizadeh and Diehn et al., Semin Radiat Oncol 25:305-312 (2015)
2166	Dudley and Diehn, Annu. Rev. Pathol. Mech. Dis. 16:199-222 (2021)
2167	RESERVED
2168	RESERVED
2169	Declaration of Henry Morrice Furneaux
2170	American Heritage Dictionary definition of “identify”
2171	https://www.aacc.org/science-and-research/clinicalchemistry/clinical-chemistry-podcasts/2013/cancer-genomescanning-in-plasma-detection-of-tumor-associated-copynumber-aberrations , EX1017, from related <i>Foresight Diagnostics Inc. v. Personalis, Inc.</i> , IPR2023-00545
2172	Lewin, “Genes V,” Oxford University Press, 1994.
2173	Quackenbush Declaration, EX1020, from related <i>Foresight Diagnostics Inc. v. Personalis, Inc.</i> , IPR2023-00545

Exhibit No.	Description
2174	Matthew W. Anderson & Iris Schrijver, “Next Generation DNA Sequencing and the Future of Genomic Medicine,” Genes (2010), EX1004, from related <i>Foresight Diagnostics Inc. v. Personalis, Inc.</i> , IPR2023-00545
2175	“No symbol” definition, https://en.wikipedia.org/wiki/No_symbol
2176	Ashford, “Dana Farber Poised to Shift ‘Profile’ Tumor Analysis Program From Research Study to Clinical Test,” Genome Web, September 16, 2016.
2177	Sholl, Institutional implementation of clinical tumor profiling on an unselected cancer population,” JD Insight. 1:e87062 (2016)
2178-2201	RESERVED
2202	[Confidential] Settlement Agreement

Respectfully submitted,

Weil, Gotshal & Manges LLP

Dated: June 28, 2024

/Derek C. Walter/

Derek C. Walter (Reg. No. 74,656)
Lead Counsel for Personalis, Inc

Nathanael R. Luman (Reg. No. 63,160)
Knobbe, Martens, Olson & Bear LLP
2040 Main St.
Irvine, CA 92614
Telephone: 949-760-0404

Counsel for Patent Owner Personalis, Inc.

CERTIFICATE OF SERVICE

I hereby certify that, pursuant to 37 C.F.R. § 42.6(e) and with the agreement of counsel for Petitioner, a true and correct copy of **PATENT OWNER'S UPDATED EXHIBIT LIST** is being served electronically on June 28, 2024, to the e-mail addresses shown below:

Andrew E. Krause, Reg. No. 76,276 IRELL & MANELLA LLP 1800 Avenue of the Stars, Ste. 900 Los Angeles, CA 90067 T: 310-277-1010 F: 310-203-7199 akrause@irell.com ForesightIPRs@irell.com	Amir Naini, Reg. No. 45,770 NAINI P.C. 2632 Wilshire Blvd., Suite 268 Santa Monica, CA 90403 T: 310- 592-3030 F: 310-453-9008 amir@nainipc.com Abigail Sellers, Reg. No. 80,391 Alan J. Heinrich (<i>Pro Hac Vice</i>) IRELL & MANELLA LLP 1800 Avenue of the Stars, Suite 900 Los Angeles, California 90067 Telephone: (310) 277-1010 Facsimile: (310) 203-7199 asellers@irell.com aheinrich@irell.com
---	---

Dated: June 28, 2024

/Derek C. Walter/
Derek C. Walter,
Lead Counsel for Personalis, Inc
Reg. No. 74,656